Product Information
FENOFIBRATE 48 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.0794 per EA under NDC 69097045905. Its NADAC has been published 499 times since Mar 15, 2017.
FDA first approved this application on Dec 15, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
48 mg/1
Manufacturer
Cipla USA Inc.NDC
69097045905
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA208709FDA Approved
12/15/2016
TE Code
AB
On Market Since
12/15/2016
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 48 MG TABLET has been published 499 times since Mar 15, 2017, and over the history we have for it it has declined 81.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0794 per EA |
|---|---|
| All-time high | $0.4370 (May 10, 2017) |
| All-time low | $0.0794 (Sep 23, 2026) |
| 52-week high | $0.0916 |
| 52-week low | $0.0794 |
| Median price | $0.1226 |
| Average price | $0.1640 |
| Largest weekly change | -23.1% (Apr 17, 2024) |
| Weeks tracked | 499 |
| Tracking since | Mar 15, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the FENOFIBRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
FENOFIBRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 48 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 48 MG TABLET, manufactured by Cipla USA Inc., is $0.0794 per EA (NDC 69097045905), effective Sep 30, 2026.
How has the price of FENOFIBRATE 48 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 48 MG TABLET has declined 81.1%. It has been tracked across 499 weekly CMS publications since Mar 15, 2017.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 48 MG TABLET?
Since Mar 15, 2017, the NADAC for FENOFIBRATE 48 MG TABLET has ranged from a low of $0.0794 (Sep 23, 2026) to a high of $0.4370 (May 10, 2017), with a median of $0.1226 per EA.
Are there cheaper alternatives to FENOFIBRATE 48 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of FENOFIBRATE 48 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FENOFIBRATE 48 MG TABLET?
FENOFIBRATE 48 MG TABLET (NDC 69097045905) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.